var data={"title":"Tinidazole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tinidazole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7057?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">see &quot;Tinidazole: Drug information&quot;</a> and <a href=\"topic.htm?path=tinidazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tinidazole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708927\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Carcinogenic:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the 2 drugs are structurally related and have similar biologic effects. Reserve its use only for the conditions for which it is indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228029\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tindamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039011\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Amebicide</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiprotozoal, Nitroimidazole</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039046\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">see &quot;Tinidazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebiasis, intestinal:</b> Children &gt;3 years and Adolescents: Oral:  50 mg/kg/day for 3 days; maximum daily dose: 2000 mg/<b>day</b>; for patients with severe and extraintestinal disease, administer for 5 days (<i>Red Book</i> [AAP], 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebiasis, liver abscess:</b> Children &gt;3 years and Adolescents: Oral:  50 mg/kg/day for 3 to 5 days; maximum daily dose: 2000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial vaginosis:</b> Adolescents: Oral: 2000 mg once daily for 2 days <b>or</b> 1000 mg once daily for 5 days (CDC, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Giardiasis:</b> Children &gt;3 years and Adolescents: Oral: 50 mg/kg as a single dose; maximum dose: 2000 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Helicobacter pylori</i> infection:</b> Limited data available: Children &gt;3 years and Adolescents: Oral: 20 mg/kg/day in 1 to 2 divided doses for 5 to 7 days in combination with other agents; some studies have used a longer duration of 2 to 6 weeks; maximum daily dose: 1000 mg/<b>day</b> (Francavilla, 2005; Moshkowitz, 1998; Nijevitch, 2000; Oderda, 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nongonococcal urethritis, recurrent/persistent:</b> Adolescents: Oral: 2000 mg as a single dose in combination with azithromycin (CDC, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichomoniasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;3 years: Oral: 50 mg/kg as a single dose; maximum dose: 2000 mg (<i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 2000 mg as a single dose; sexual partners should be treated at the same time; if treatment failure, can consider extended regimen of 2000 mg once daily for 5 days (CDC, 2010; <i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebiasis, intestinal:</b> Oral: 2000 mg/day for 3 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebiasis, liver abscess:</b> Oral: 2000 mg/day for 3 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial vaginosis:</b> Oral: 2000 mg/day for 2 days <b>or</b> 1000 mg/day for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Giardiasis:</b> Oral:  2000 mg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichomoniasis:</b> Oral: 2000 mg as a single dose; sexual partners should be treated at the same time </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &gt;3 years, Adolescents, and Adults: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Approximately 43% removed during a 6-hour session; an additional dose equal to  <sup>1</sup>/<sub>2</sub> the usual dose should be administered at the end of hemodialysis if tinidazole is administered prior to hemodialysis on dialysis days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228005\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tindamax: 250 mg [DSC], 500 mg [scored; contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227992\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039052\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:  Administer with food to minimize gastrointestinal adverse effects. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228023\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039012\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of giardiasis caused by <i>G. duodenalis</i> (<i>G. lamblia</i>) (FDA approved in ages &gt; 3 years and adults); treatment of intestinal amebiasis and amebic liver abscess caused by <i>E. histolytica</i> (FDA approved in ages &gt;3 years and adults); treatment of trichomoniasis caused by <i>T. vaginalis</i> (FDA approved in adults); treatment of bacterial vaginosis caused  by <i>Bacteroides</i> spp, <i>Gardnerella vaginalis</i>, and <i>Prevotella</i> spp (FDA approved in nonpregnant adult females)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228053\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, burning sensation, dizziness, drowsiness, fatigue, headache, insomnia, malaise, peripheral neuropathy (transient; includes numbness and paresthesia), seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Body odor (vaginal), diaphoresis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypermenorrhea, increased thirst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, constipation, decreased appetite, diarrhea, dysgeusia (bitter taste, metallic taste), dyspepsia, epigastric distress, flatulence, nausea, oral candidiasis, salivation, stomatitis, tongue discoloration, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dark urine, dysuria, pelvic pain, urine abnormality, vaginal discharge, vulvovaginal candidiasis, vulvovaginal disease (discomfort)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia (transient), neutropenia (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis (overgrowth)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Bronchospasm, coma, confusion, depression, dyspnea, erythema multiforme, hairy tongue, hypersensitivity reaction (acute, severe), pharyngitis, Stevens-Johnson syndrome, thrombocytopenia (reversible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228011\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tinidazole, nitroimidazole derivatives, or any component of the formulation; pregnancy (first trimester); breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227994\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic: <b>[US Boxed Warning]: Carcinogenicity has been observed with another nitroimidazole derivative (metronidazole) in animal studies;</b> <b>use should be reserved for approved indications only.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Seizures and peripheral neuropathy (eg, extremity numbness and paresthesia) have been reported with tinidazole and other nitroimidazole derivatives; discontinue treatment if abnormal neurologic signs or symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD), pseudomembranous colitis, and/or vaginal candidiasis. CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Use with caution in patients with current or a history of blood dyscrasias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with current or a history of hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228043\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227999\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95047&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Tinidazole may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: Tinidazole may enhance the adverse/toxic effect of Disulfiram. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228024\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected. Management: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228002\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228013\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer contraindicates use of tinidazole during the first trimester of pregnancy. Adverse events have been observed in some animal reproduction studies. Tinidazole crosses the human placenta and enters the fetal circulation. The safety of tinidazole for the treatment of bacterial vaginosis or trichomoniasis in pregnant women has not been well evaluated. Other agents are preferred for use during pregnancy (CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227993\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">After diffusing into the organism, it is proposed that tinidazole causes cytotoxicity by damaging DNA and preventing further DNA synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228010\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~50 L; distributes to most body tissues and fluids; crosses the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 (primarily); undergoes oxidation, hydroxylation and conjugation; forms a metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 13.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1.6 hours (fasting, delayed ~2 hours when given with food)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~20% to 25%); feces (~12%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228009\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 67 mg/mL suspension may be made with tablets and cherry syrup. Crush four 500 mg tablets in a mortar and reduce to a fine powder. Add 10 mL cherry syrup and mix to a uniform paste; mix while adding cherry syrup in incremental proportions to <b>almost</b> 30 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 30 mL. Label &quot;shake well&quot;. Stable for 7 days.</p>\n    <div class=\"reference\">Tindamax&reg; prescribing information, Mission Pharmacal Company, San Antonio, TX, 2007. <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf&amp;token=P4I+jnF23RyZ76rzysOuoT7oXyT52lNB6bVsfGmRKZ4kmuE8PbTrGNkLvTx+LSV1ksaZZeEbTnrFpdj/n2BI0RQWy6LpShjHJ4+j4remjzk=&amp;TOPIC_ID=95047\" target=\"_blank\">Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf</a></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422283\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tindamax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $342.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tinidazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (40): $203.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $203.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228016\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amibiol (CO);</li>\n      <li>Asgin (TW);</li>\n      <li>Astiba (ET);</li>\n      <li>Cachtin (ET);</li>\n      <li>Dyzole (NZ);</li>\n      <li>Estovit-T (MX);</li>\n      <li>Fasdol (EC);</li>\n      <li>Fasigin (IT, PL);</li>\n      <li>Fasigyn (AE, AR, AT, BE, BG, BH, BZ, CH, CL, CO, CR, EG, GR, GT, HN, IL, IN, JO, KW, LB, LU, MX, NI, NL, PA, PE, PK, PT, QA, RU, SA, SE, SG, SI, SV, TH, UY, VE, VN, ZA);</li>\n      <li>Fasigyne (FR);</li>\n      <li>Fazyzhyn (UA);</li>\n      <li>Induken (MX);</li>\n      <li>Jie Li (CN);</li>\n      <li>Protogyn (AE, BD, BH, JO, LB, QA, SA);</li>\n      <li>Protozole (ET);</li>\n      <li>Simplotan (AT);</li>\n      <li>Su (TW);</li>\n      <li>T-Zol (BD);</li>\n      <li>Tindol (MY);</li>\n      <li>Tiniba (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Tinidan (EC);</li>\n      <li>Tinidazine (KR);</li>\n      <li>Tinirem (ET, TR);</li>\n      <li>Tinizol (BD, CR, DO, GT, HN, NI, PA, RO, SV);</li>\n      <li>Tinoral (BR);</li>\n      <li>Tiprogyn (RO);</li>\n      <li>Tricolam (ES);</li>\n      <li>Tricor 500 (PY);</li>\n      <li>Trinigyn (BB, BM, BS, GY, JM, SR, TT);</li>\n      <li>Troxxil (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for <i>Helicobacter pylori</i> eradication in children:  a randomized trial. <i>Gastroenterology</i>. 2005;129:1414-1419.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/16285942/pubmed\" target=\"_blank\" id=\"16285942\">16285942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamp KC, Freeman CD, Klutman NE, &ldquo;Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials,&rdquo; <i>Clin Pharmacokinet</i>, 1999, 36(5):353-73.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moshkowitz M, Reif S, Brill S, Ringel Y, Arber N, Halpern Z, Bujanover Y. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for <i>Helicobacter pylori</i> infection in children and adolescents. <i>Pediatrics</i>. 1998;102(1):e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/9651466/pubmed\" target=\"_blank\" id=\"9651466\">9651466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nijevitch AA, Farztdinov KM, Sataev VU, et al. <i>Helicobacter pylori infection</i> in childhood: results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole. <i>Journal of Gastroenterology and Hepatology</i>. 2000;15:1243-1250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/11129216/pubmed\" target=\"_blank\" id=\"11129216\">11129216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Odera G, Vaira D, Ainley C, et al. Eighteen month follow up of <i>Helicobacter pylori</i> positive children treated with amoxicillin and tinidazole. <i>Gut</i>. 1992;33:1328-1330.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/1446854/pubmed\" target=\"_blank\" id=\"1446854\">1446854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95047 Version 50.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708927\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F228029\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1039011\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1039046\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F228005\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F227992\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1039052\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F228023\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1039012\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F228053\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F228011\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227994\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F228043\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F227999\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F228024\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F228002\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F228013\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227993\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F228010\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F228009\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422283\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F228016\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/95047|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">Tinidazole: Drug information</a></li><li><a href=\"topic.htm?path=tinidazole-patient-drug-information\" class=\"drug drug_patient\">Tinidazole: Patient drug information</a></li></ul></div></div>","javascript":null}